Skip to main content

Table 2 HPP-related disease history in different subtypes of HPP

From: Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children

 

Perinatal HPP

Infantile HPP

Childhood HPP

Total

(n = 4)

(n = 17)

(n = 29)

(n = 50)

Systemic manifestations

 Impairment of motor skills

3/4 (75%)

16/17 (94%)

20/29 (69%)

39/50 (78%)

 Speech developmental delay

2/4 (50%)

3/17 (18%)

5/29 (17%)

10/50 (20%)

 Failure to thrive

2/4 (50%)

12/17 (71%)

17/29 (59%)

31/50 (62%)

 Pulmonary abnormalities

4/4 (100%)

11/17 (65%)

5/29 (17%)

20/50 (40%)

 Cardiac abnormalities

2/4 (50%)

5/17 (29%)

6/29 (21%)

13/50 (26%)

 Nephrocalcinosis

2/4 (50%)

13/17 (76%)

5/29 (17%)

19/50 (38%)

 Cerebral seizures

4/4 (100%)

0/17 (0%)

0/29 (0%)

4/50 (8%)

 Gastrointestinal abnormalities

3/4 (75%)

7/17 (41%)

6/29 (21%)

16/50 (32%)

 Musculoskeletal pain

1/4 (25%)

7/17 (41%)

16/29 (55%)

24/50 (48%)

 Difficulties in swallowing

2/4 (50%)

7/17 (41%)

8/29 (28%)

17/50 (34%)

Osseous manifestations

 Impairment of mineralization

4/4 (100%)

15/17 (88%)

18/29 (62%)

36/50 (72%)

 Pathologic fractures

1/4 (25%)

4/17 (24%)

1/29 (3%)

6/50 (12%)

 Chronic non-bacterial osteomyelitis/osseous inflammation

0/4 (0%)

4/17 (24%)

3/29 (10%)

7/50 (14%)

 Craniosynostosis

3/4 (75%)

13/17 (76%)

8/29 (28%)

24/50 (48%)

Dental manifestations

 Premature loss-of-teeth

2/4 (50%)

10/17 (59%)

20/29 (69%)

32/50 (64%)

 Caries/deficient enamel

1/4 (25%)

2/17 (12%)

7/29 (24%)

10/50 (20%)